2 Kidney Disease Risk Reduction In addition, the FDA has approved semaglutide (Ozempic) to slow the progression of kidney disease and reduce the risk of kidney failure, making it the most widely indicated GLP-1 drug
You can also report side effects directly via the Yellow Card Scheme, website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store
Obesity Nearly all respondents cover GLP-1s for type 2 diabetes (T2D), versus only 39% who provide coverage for obesity
The CNS GLP- 1 receptors are not necessary for the physiological regulation of blood glucose levels by endogenous GLP- 1 or the pharmacological control of glucose homeostasis that depends on GLP- 1 receptors, although further research is needed to investigate the possible role of GLP- 1 receptors expressed outside the beta cell, including within the enteric and peripheral nervous systems, in improving beta cell function through enteral glucose mediation [70, 84]
10.1007/s11356-023-28474-0 48